AU2004262927B2 - Combinations comprising staurosporines - Google Patents

Combinations comprising staurosporines Download PDF

Info

Publication number
AU2004262927B2
AU2004262927B2 AU2004262927A AU2004262927A AU2004262927B2 AU 2004262927 B2 AU2004262927 B2 AU 2004262927B2 AU 2004262927 A AU2004262927 A AU 2004262927A AU 2004262927 A AU2004262927 A AU 2004262927A AU 2004262927 B2 AU2004262927 B2 AU 2004262927B2
Authority
AU
Australia
Prior art keywords
typically
alkyl
methyl
phenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004262927A
Other languages
English (en)
Other versions
AU2004262927A1 (en
Inventor
Peter Wisdom Atadja
Kapil N. Bhalla
Pamela Sarah Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004262927A1 publication Critical patent/AU2004262927A1/en
Priority to AU2008202050A priority Critical patent/AU2008202050A1/en
Application granted granted Critical
Publication of AU2004262927B2 publication Critical patent/AU2004262927B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004262927A 2003-08-08 2004-08-06 Combinations comprising staurosporines Ceased AU2004262927B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008202050A AU2008202050A1 (en) 2003-08-08 2008-05-08 Combinations comprising staurosporines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49382803P 2003-08-08 2003-08-08
US60/493,828 2003-08-08
PCT/EP2004/008848 WO2005014004A1 (en) 2003-08-08 2004-08-06 Combinations comprising staurosporines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008202050A Division AU2008202050A1 (en) 2003-08-08 2008-05-08 Combinations comprising staurosporines

Publications (2)

Publication Number Publication Date
AU2004262927A1 AU2004262927A1 (en) 2005-02-17
AU2004262927B2 true AU2004262927B2 (en) 2008-05-22

Family

ID=34135288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004262927A Ceased AU2004262927B2 (en) 2003-08-08 2004-08-06 Combinations comprising staurosporines

Country Status (9)

Country Link
US (1) US20070191338A1 (https=)
EP (2) EP1653973A1 (https=)
JP (1) JP2007501774A (https=)
CN (1) CN100536850C (https=)
AU (1) AU2004262927B2 (https=)
BR (1) BRPI0413439A (https=)
CA (1) CA2533861A1 (https=)
MX (1) MXPA06001524A (https=)
WO (1) WO2005014004A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
KR20080046161A (ko) * 2005-08-09 2008-05-26 요하네스 구텐베르크-유니버시타트 마인츠 비-소세포 폐암의 치료를 위한 스타우로스포린 유도체
WO2007030455A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
GEP20125708B (en) 2008-03-26 2012-12-10 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
WO2014009609A1 (en) 2012-07-13 2014-01-16 Turun Yliopisto Combination therapy iii

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919244A2 (de) * 1997-10-10 1999-06-02 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Kombinationspräparate für die Therapie von Tumoren

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB8803048D0 (en) 1988-02-10 1988-03-09 Hoffmann La Roche Substituted pyrroles
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
PH30300A (en) 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU2565795A (en) 1994-06-01 1995-12-21 Ciba-Geigy Ag Carbazole derivatives as agents against multi-drug resistance
EP0763042A1 (en) 1994-06-01 1997-03-19 Novartis AG Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711557A1 (de) 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733372A3 (de) 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
NL1003692C2 (nl) 1996-07-26 1998-01-28 Stork Protecon Langen Bv Inrichting voor het afscheiden van vleesmassa van van vleesresten voorziene botten.
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
DE60213842T2 (de) * 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
BRPI0409227C1 (pt) * 2003-04-07 2021-05-25 Axys Pharm Inc composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919244A2 (de) * 1997-10-10 1999-06-02 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Kombinationspräparate für die Therapie von Tumoren

Also Published As

Publication number Publication date
CN1832747A (zh) 2006-09-13
EP1653973A1 (en) 2006-05-10
MXPA06001524A (es) 2006-05-15
JP2007501774A (ja) 2007-02-01
WO2005014004A1 (en) 2005-02-17
AU2004262927A1 (en) 2005-02-17
CN100536850C (zh) 2009-09-09
EP2305265A1 (en) 2011-04-06
US20070191338A1 (en) 2007-08-16
CA2533861A1 (en) 2005-02-17
BRPI0413439A (pt) 2006-10-17

Similar Documents

Publication Publication Date Title
CA2462657C (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AU2004262927B2 (en) Combinations comprising staurosporines
AU2004244747B2 (en) Staurosporine derivatives for hypereosinophilic syndrome
CA2527703C (en) New use of staurosporine derivatives
CA2629478C (en) Staurosporine derivatives for use in alveolar rhabdomyosarcoma
AU2008202050A1 (en) Combinations comprising staurosporines
AU2005313556B2 (en) Use of staurosporine derivatives for the treatment of multiple Myeloma
WO2006021456A1 (en) Combination comprising a staurosporine and a cyp3a4 inhibitor
WO2008043811A1 (en) Staurosporine derivatives and radiation
AU2008201869A1 (en) Staurosporine derivatives for hypereosinophilic syndrome
MX2008006287A (es) Derivados de estaurosporina para utilizarse en rabdomiosarcoma alveolar.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired